Liraglutide 3.0 mg: SCALE Programme Outcomes and Evidence Review

Liraglutide was the first GLP-1 receptor agonist approved specifically for weight management in adults — predating semaglutide's obesity indication by nearly six years. The SCALE programme established the foundational RCT evidence base for GLP-1-based anti-obesity pharmacotherapy, and liraglutide's real-world track record now spans more than a decade.

Pharmacology and Approved Formulations

Liraglutide is a GLP-1 analogue with 97% homology to native human GLP-1. A lysine-to-arginine substitution at position 26, combined with the attachment of a C-16 fatty acid chain via a glutamate–two-OEG spacer, enables reversible albumin binding and reduces renal clearance. The resulting half-life of approximately 13 hours supports once-daily subcutaneous injection. Unlike semaglutide, no oral formulation exists for liraglutide.

Two doses are approved in the USA: Victoza (liraglutide 1.2–1.8 mg daily) for type 2 diabetes mellitus, approved by the FDA in 2010, and Saxenda (liraglutide 3.0 mg daily) for chronic weight management in adults with BMI ≥30 kg/m² or ≥27 with at least one weight-related comorbidity, approved in 2014. Both are manufactured by Novo Nordisk.

The SCALE Programme: Core Efficacy Data

The Satiety and Clinical Adiposity — Liraglutide Evidence (SCALE) programme comprised four pivotal trials. SCALE Obesity and Prediabetes (n=3,731) is the largest, enrolling adults with obesity or overweight with comorbidities. At 56 weeks, liraglutide 3.0 mg produced a mean weight reduction of 8.0% from baseline versus 2.6% with placebo (treatment difference: −5.4%; 95% CI −5.8 to −5.0; p<0.001). The proportion achieving ≥5% weight loss was 63.2% with liraglutide versus 27.1% with placebo.

The numbers appear more modest than the semaglutide STEP data — mean 8% versus 14.9% — and that comparison is frequently raised in clinical practice. Three contextual points merit attention. First, the SCALE and STEP trials used different primary endpoints and follow-up durations (56 vs 68 weeks), complicating direct comparison. Second, the populations enrolled differed in baseline BMI and comorbidity burden. Third, liraglutide's dose-response curve at 3.0 mg is near-plateau; semaglutide's dose-response remains steeper at doses achievable in the weekly formulation.

SCALE Diabetes (n=846) enrolled adults with T2DM and showed 6.0% weight reduction at 56 weeks versus 2.0% with placebo. SCALE Maintenance examined adults who had already lost ≥5% of body weight during a low-calorie diet run-in; those randomised to liraglutide maintained their loss and achieved an additional 6.3% reduction over 56 weeks, versus a 0.1% gain in the placebo group — a clinically important weight regain prevention finding.

LEADER: Cardiovascular Outcomes in Type 2 Diabetes

The Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results (LEADER) trial enrolled 9,340 adults with T2DM and high cardiovascular risk over a median 3.8 years. The primary three-point MACE endpoint occurred in 13.0% of the liraglutide group versus 14.9% of the placebo group (HR 0.87; 95% CI 0.78–0.97; p=0.01 for superiority). Cardiovascular death was specifically reduced (4.7% vs 6.0%, HR 0.78), an effect that has shaped thinking about the mechanism — possibly reflecting direct cardiac GLP-1R effects beyond weight loss.

Tolerability and Real-World Adherence

The tolerability profile of liraglutide 3.0 mg mirrors that of the class, but the daily injection burden substantially affects adherence in real-world populations. Nausea was reported in approximately 39% of SCALE participants on active treatment, with the peak incidence during the 4-week titration phase (starting at 0.6 mg daily and escalating by 0.6 mg weekly to the 3.0 mg maintenance dose). Vomiting occurred in roughly 15%. The majority of patients with initial GI symptoms either resolved spontaneously or required only titration adjustment.

Real-world persistence data are illuminating and somewhat sobering. An analysis of US claims data (Wilkinson et al., 2020) found that only 33% of patients initiating Saxenda remained on treatment at 12 months. Adherence-adjusted weight loss was, predictably, substantially lower than in controlled trial settings. This differential between RCT efficacy and real-world effectiveness — a ubiquitous phenomenon in chronic disease pharmacotherapy — is particularly pronounced for injectable daily medications.

Gallbladder events: the lipogenic shift associated with rapid weight loss increases biliary cholesterol saturation. Cholelithiasis incidence was 2.2% with liraglutide versus 0.8% with placebo across SCALE trials. Clinicians should maintain a low threshold for abdominal ultrasound in patients reporting right upper quadrant symptoms.